LIGAND PHARMACEUTICALS INCLGNDEarnings & Financial Report
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also own...
LGND Q3 2025 Key Financial Metrics
Revenue
$115.5M
Gross Profit
N/A
Operating Profit
$54.9M
Net Profit
$117.3M
Gross Margin
N/A
Operating Margin
47.6%
Net Margin
101.6%
YoY Growth
122.8%
EPS
$5.68
Financial Flow
LIGAND PHARMACEUTICALS INC Q3 2025 Financial Summary
LIGAND PHARMACEUTICALS INC reported revenue of $115.5M for Q3 2025, with a net profit of $117.3M (101.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $115.5M |
|---|---|
| Net Profit | $117.3M |
| Gross Margin | N/A |
| Operating Margin | 47.6% |
| Report Period | Q3 2025 |
LIGAND PHARMACEUTICALS INC Annual Revenue by Year
LIGAND PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $167.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $167.1M |
| 2023 | $131.3M |
| 2022 | $196.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.1M | $31.0M | $41.5M | $51.8M | $42.8M | $45.3M | $47.6M | $115.5M |
| YoY Growth | 3.9% | -29.6% | 57.5% | 57.6% | 52.4% | 46.3% | 14.7% | 122.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $787.2M | $913.9M | $866.4M | $954.9M | $941.8M | $905.4M | $948.6M | $1.48B |
| Liabilities | $86.3M | $107.3M | $91.2M | $113.7M | $111.3M | $109.9M | $120.1M | $526.6M |
| Equity | $700.9M | $806.5M | $775.2M | $841.2M | $830.4M | $795.5M | $828.5M | $950.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $8.1M | $18.7M | $13.3M | $36.5M | $28.5M | $-25.4M | $15.8M | $13.1M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M